NCT01288911 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 184
- group Id
- BG001
- value
- 191
- group Id
- BG002
- value
- 375
- units
- Participants
- groups
- description
- Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
- id
- BG000
- title
- Enzalutamide
- description
- Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
- id
- BG001
- title
- Bicalutamide
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.22
- value
- 70.3
- group Id
- BG001
- spread
- 8.89
- value
- 71.1
- group Id
- BG002
- spread
- 9.05
- value
- 70.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 47
- group Id
- BG002
- value
- 92
- title
- < 65 years
- categories
- measurements
- group Id
- BG000
- value
- 85
- group Id
- BG001
- value
- 80
- group Id
- BG002
- value
- 165
- title
- 65-75 years
- categories
- measurements
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 118
- title
- > 75 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Female
- measurements
- group Id
- BG000
- value
- 184
- group Id
- BG001
- value
- 191
- group Id
- BG002
- value
- 375
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 172
- group Id
- BG001
- value
- 176
- group Id
- BG002
- value
- 348
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 18
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 184
- group Id
- BG001
- value
- 187
- group Id
- BG002
- value
- 371
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 4
- title
- Hispanic or Latino
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 87
- group Id
- BG001
- value
- 76
- group Id
- BG002
- value
- 163
- title
- Before diagnosis of metastasis
- measurements
- group Id
- BG000
- value
- 97
- group Id
- BG001
- value
- 115
- group Id
- BG002
- value
- 212
- title
- After diagnosis of metastasis
- param Type
- COUNT_OF_PARTICIPANTS
- title
- LHRH agonist/antagonist initiation or bilateral orchiectomy relative to diagnosis of metastasis
- unit Of Measure
- Participants
- population Description
- The baseline analysis population consisted of all participants that were randomized to receive study drug.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 184
- group Id
- BG001
- value
- 191
- group Id
- BG002
- value
- 375
- units
- Participants
- groups
- description
- Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
- id
- BG000
- title
- Enzalutamide
- description
- Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
- id
- BG001
- title
- Bicalutamide
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.22
- value
- 70.3
- group Id
- BG001
- spread
- 8.89
- value
- 71.1
- group Id
- BG002
- spread
- 9.05
- value
- 70.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 47
- group Id
- BG002
- value
- 92
- title
- < 65 years
- categories
- measurements
- group Id
- BG000
- value
- 85
- group Id
- BG001
- value
- 80
- group Id
- BG002
- value
- 165
- title
- 65-75 years
- categories
- measurements
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 118
- title
- > 75 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Female
- measurements
- group Id
- BG000
- value
- 184
- group Id
- BG001
- value
- 191
- group Id
- BG002
- value
- 375
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 172
- group Id
- BG001
- value
- 176
- group Id
- BG002
- value
- 348
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 18
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 184
- group Id
- BG001
- value
- 187
- group Id
- BG002
- value
- 371
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 4
- title
- Hispanic or Latino
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 87
- group Id
- BG001
- value
- 76
- group Id
- BG002
- value
- 163
- title
- Before diagnosis of metastasis
- measurements
- group Id
- BG000
- value
- 97
- group Id
- BG001
- value
- 115
- group Id
- BG002
- value
- 212
- title
- After diagnosis of metastasis
- param Type
- COUNT_OF_PARTICIPANTS
- title
- LHRH agonist/antagonist initiation or bilateral orchiectomy relative to diagnosis of metastasis
- unit Of Measure
- Participants
- population Description
- The baseline analysis population consisted of all participants that were randomized to receive study drug.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle